scholarly journals Effect of Vitamin D Supplement on Vulvovaginal Atrophy of the Menopause

Nutrients ◽  
2020 ◽  
Vol 12 (9) ◽  
pp. 2876 ◽  
Author(s):  
Thawinee Kamronrithisorn ◽  
Jittima Manonai ◽  
Sakda Arj-Ong Vallibhakara ◽  
Areepan Sophonsritsuk ◽  
Orawin Vallibhakara
Keyword(s):  
Vitamin D ◽  
Postmenopausal Women ◽  
Controlled Trial ◽  
Placebo Treatment ◽  
Vitamin D Supplementation ◽  
Oral Vitamin ◽  
Vulvovaginal Atrophy ◽  
Vaginal Ph ◽  
Vaginal Health ◽  
The Mean

The effects of oral vitamin D supplements on vaginal health in postmenopausal women with vulvovaginal atrophy (VVA) was evaluated. A double-blinded, randomized placebo-controlled trial was conducted for 12 weeks to investigate changes on vaginal maturation index (VMI), vaginal pH, and the visual analog scale (VAS) of VVA symptoms. The vitamin D group received oral ergocalciferol, at 40,000 IU per week, while the placebo group received an identical placebo capsule. Eighty postmenopausal women were enrolled. There were no significant differences in baseline characteristics between both groups. In an intention-to-treat analysis, VMI, vaginal pH, and VAS of VVA symptoms showed no significant differences between both groups at the six and 12 weeks. However, the mean difference of VMI in the vitamin D group between baseline and at six weeks showed significant improvement (5.5 + 16.27, p <0.05). Moreover, the mean vaginal pH and VAS of VVA patients in the vitamin D group were significantly improved at both six and 12 weeks compared to baseline. The oral vitamin D supplementation for 12 weeks potentially improves vaginal health outcomes in postmenopausal women with VVA symptoms, demonstrated by the improved mean VMI, vaginal pH, and VAS at six and 12 weeks between baseline, however, no significant differences were observed from the placebo treatment.

scholarly journals The Clinical Effect of Oral Vitamin D2 Supplementation on Psoriasis: A Double-Blind, Randomized, Placebo-Controlled Study

2019 ◽  
Vol 2019 ◽  
pp. 1-9 ◽  
Author(s):  
Wareeporn Disphanurat ◽  
Wongsiya Viarasilpa ◽  
Panlop Chakkavittumrong ◽  
Padcha Pongcharoen
Keyword(s):  
Vitamin D ◽  
Placebo Group ◽  
Adverse Events ◽  
Clinical Effect ◽  
Vitamin D Supplementation ◽  
P Value ◽  
Vitamin D2 ◽  
Oral Vitamin ◽  
Pasi Score ◽  
The Mean

Background. There are limited randomized controlled trials of oral vitamin D supplementation in psoriasis, especially in Asia, and the results are inconclusive. Objective. To investigate the clinical effect of oral vitamin D supplementation on psoriasis. Methods. Patients with psoriasis were randomized to receive vitamin D2 60,000 IU or similar-looking placebo pills once every 2 weeks for 6 months. The primary outcome was improvement of the Psoriasis Area and Severity Index (PASI) score at 3 and 6 months after treatment. Serum levels of 25(OH)D, calcium, phosphate, parathyroid hormone, and C-reactive protein and adverse events were monitored. The chi-square test, Fisher’s exact test, Student’s t-test, and Spearman’s correlation analysis were used in statistical analysis. Results. Of 50 subjects screened, 45 were eligible and randomized to the oral vitamin D2 group (n=23) or placebo group (n=22). At enrollment, the mean PASI score was 4.45, and 26.7% of patients had vitamin D deficiency. At 3 months, the oral vitamin D2 group had significantly higher PASI improvement than the placebo group (mean PASI improvement: 1.43 versus [vs.] -0.33, p-value=0.034; mean %PASI improvement: 34.21% vs. -1.85%, p-value=0.039). The mean serum 25(OH)D level was significantly higher in the oral vitamin D group than in the placebo group (27.4 vs. 22.4 ng/mL, p-value=0.029). Serum 25(OH)D concentrations were significantly inversely correlated with PASI scores at the 6-month follow-up. No major adverse event was observed overall. Conclusion. Oral vitamin D2 supplementation in patients with psoriasis increased the serum vitamin D level and significantly improved the treatment outcome without increasing adverse events. Trial Registration. This trial is registered with Thai Clinical Trials Registry TCTR20180613001.

scholarly journals The effects of oral vitamin D supplementation on the prevention of peritoneal dialysis-related peritonitis: study protocol for a randomized controlled clinical trial

Trials ◽  
2019 ◽  
Vol 20 (1) ◽  
Author(s):  
Yu-hui Zhang ◽  
Xiao Xu ◽  
Hai-chen Pi ◽  
Zhi-kai Yang ◽  
David W. Johnson ◽  
...  
Keyword(s):  
Vitamin D ◽  
Randomized Controlled Trial ◽  
Peritoneal Dialysis ◽  
Controlled Trial ◽  
Pilot Trial ◽  
Vitamin D Supplementation ◽  
Control Group ◽  
Oral Vitamin ◽  
Randomized Controlled ◽  
Randomized Controlled Trail

Abstract Background Vitamin D deficiency has been shown to be closely associated with peritoneal dialysis (PD)-related peritonitis. The aim of this study is to examine the feasibility of conducting a large, powered randomized controlled trial to determine the effects of vitamin D supplementation on the risk of PD-related peritonitis in patients who have already experienced an episode of peritonitis. Methods This prospective, open-label randomized controlled pilot trial with blinded end-points aims to determine the feasibility of oral vitamin D supplementation and to explore its effects on the risk of subsequent PD-related peritonitis among PD patients who have recovered from a recent episode of peritonitis. Eligible patients will be randomized 1:1 to either oral vitamin D supplementation (2000 IU per day; intervention group) or no vitamin D supplementation (control group) in addition to usual care according to International Society for Peritoneal Dialysis guidelines. The sample size will be 30 patients for both groups. All participants will be followed for 12 months. The primary outcome is the assessment of feasibility (recruitment success, retention, adherence, safety) and fidelity (change in serum 25-hydroxyvitamin D level during follow-up) for a large, powered randomized controlled trial to determine the effects of vitamin D on the risk of PD-related peritonitis in the future. Secondary outcomes include time to peritonitis occurrence, recovery of peritonitis, peritonitis-related transition to hemodialysis, and peritonitis-related death (defined as death within 30 days of peritonitis onset). Discussion This is the first randomized controlled trail investigating the effects of vitamin D supplementation on the risk of subsequent PD-related peritonitis among patients on PD. The findings for this pilot study will determine the feasibility of conducting a full-scale randomized controlled trail, which may provide a new strategy for preventing PD-related peritonitis among PD patients. Trial registration Clinicaltrails.gov, NCT03264625. Registered on 29 August 2017.

scholarly journals Circulating 25-Hydroxyvitamin D Levels in Fully Breastfed Infants on Oral Vitamin D Supplementation

2010 ◽  
Vol 2010 ◽  
pp. 1-5 ◽  
Author(s):  
Carol L. Wagner ◽  
Cindy Howard ◽  
Thomas C. Hulsey ◽  
Ruth A. Lawrence ◽  
Sarah N. Taylor ◽  
...  
Keyword(s):  
Vitamin D ◽  
Vitamin D Supplementation ◽  
Vitamin Supplementation ◽  
Oral Vitamin ◽  
Oil Emulsion ◽  
Hydroxyvitamin D ◽  
Breastfed Infants ◽  
25 Hydroxyvitamin D ◽  
The Mean ◽  
Nutritional Vitamin

Objective. To examine the effectiveness of oral vitamin (400 IU) supplementation on the nutritional vitamin D status of breastfeeding infants.Design. As part of a larger ongoing vitamin D RCT trial of lactating women, infants of mothers assigned to control received 1 drop of 400 IU vitamin /day starting at one month of age. Infant 25(OH)D levels (mean S.D.) were measured by RIA at visits 1, 4, and 7.Results. The infant mean S.D. 25(OH)D at baseline was 16.0 9.3 ng/mL (range 1.0–40.8; ); 24 (72.7%) had baseline levels <20 ng/mL (consistent with deficiency). The mean levels increased to 43.6 14.1 (range 18.2–69.7) at 4 months and remained relatively unchanged at month 7: 42.5 12.1 ng/mL (range 18.9–67.2). The change in values between 1 and 4 months and 1 and 7 months was statistically significant , and despite a decrease in dose per kilogram, values were not significantly different between months 4 and 7 .Conclusions. Oral vitamin supplementation as an oil emulsion was associated with significant and sustained increases in 25(OH)D from baseline in fully breastfeeding infants through 7 months.

Self-Directed Oral Vitamin D Supplementation in Professional Ballet Dancers: A Randomized Controlled Trial Pilot Study

2019 ◽  
Vol 23 (3) ◽  
pp. 91-96
Author(s):  
Fiachra E. Rowan ◽  
Harry Benjamin-Laing ◽  
Aedín Kennedy ◽  
Akbar De Medici ◽  
Ian Beasley ◽  
...  
Keyword(s):  
Vitamin D ◽  
Randomized Controlled Trial ◽  
Pilot Study ◽  
Controlled Trial ◽  
Vitamin D Supplementation ◽  
Oral Vitamin ◽  
Ballet Dancers ◽  
Randomized Controlled

scholarly journals Effect of Prenatal Vitamin D Supplementation on Placental Angiogenic Factors in Bangladesh (FS08-07-19)

2019 ◽  
Vol 3 (Supplement_1) ◽  
Author(s):  
Anita Subramanian ◽  
Casey Carr ◽  
Eszter Papp ◽  
Kellie Murphy ◽  
Abdullah Al Mahmud ◽  
...  
Keyword(s):  
Vitamin D ◽  
Growth Factor ◽  
Controlled Trial ◽  
Secondary Analysis ◽  
Vitamin D Supplementation ◽  
Angiogenic Factors ◽  
Fetal Sex ◽  
Maternal Vitamin ◽  
The Mean ◽  
The Impact

Abstract Objectives To determine the effect of prenatal vitamin D supplementation on expression of angiogenic factors in the placenta. Methods This is a secondary analysis of the Maternal Vitamin D for Infant Growth trial, a randomized controlled trial of maternal vitamin D supplementation in Dhaka, Bangladesh. We examined the expression of angiogenic factors in placental tissues. Women (n = 1300) were enrolled at 17–24 weeks gestation and randomized to receive: placebo, 4200 IU/week, 16,800 IU/week or 28,000 IU/week until delivery. We examined a subset of randomly selected placentas (n = 80) collected at birth, which included 20 tissues (10 male & 10 female offspring) from each treatment group in maternal/fetal pairs. A full thickness placental core was collected; fixed in formalin and embedded in paraffin. Tissue sections were stained for vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) using immunofluorescence. ImageJ was used to quantify intensity and % area of expression. T-tests were used to estimate the effects of each vitamin D dose on expression of angiogenic factors, compared to placebo. Interactions by fetal sex were also examined. Results The mean (SD) for % area of expression was 17.0 (4.0) for VEGF and 14.8 (1.9) for PlGF. The mean (SD) for intensity was 6520 (1549) for VEGF and 5716 (734) for PlGF. There were no significant differences in VEGF and PlGF between any vitamin D treatment groups versus placebo for % area or intensity of expression (Table 1). The effect of vitamin D treatment was not modified by fetal sex. Conclusions Vitamin D supplementation starting from mid-pregnancy until delivery did not effect expression of two key angiogenic factors in the placenta at term. The impact of periconception vitamin D supplementation on expression of angiogenic factors in the placenta remains unknown. Funding Sources Bill and Melinda Gates Foundation. Supporting Tables, Images and/or Graphs

Sign in / Sign up

Export Citation Format

Share Document